Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $12.00 → $4.00 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $10.00 | Buy | HC Wainwright & Co. |
| 8/11/2021 | $33.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
-- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into
NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co
Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously
HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00
Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele
BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical
BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia. “We are exc
SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. The Dow traded up 1.50% to 31,547.65 while the NASDAQ rose 1.04% to 10,972.47. The S&P 500 also rose, gaining, 1.38% to 3,804.48. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 2.1% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ:PCVX) and IMARA Inc. (NASDAQ:IMRA). In trading on Monday, materials shares fell by 0.3%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PM
The Dow Jones dropped by around 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 NGM Biopharmaceuticals The Trade: NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Director David Goeddel V bought a total of 130,000 shares at an average price of $3.56. To acquire these shares,